Ozempic is not indicated for weight loss Rate of MACE events by weight-loss category with 95% CI SUSTAIN 6: Post hoc analysis 3 Study design: The primary objective of the observational, post hoc analysis of SUSTAIN 6 was to examine the incidence rate of 3-point major adverse cardiovascular events (MACE) (nonfatal ischemic stroke, nonfatal MI, and CV death) by weight-loss categories during the first 13 months after initiation of Ozempic injection (N=1479)
GLP-1 treatment is available on the NHS if you meet specific criteria: BMI 35 kg/m (or 32.5 kg/m for certain ethnic groups) with at least one weight-related comorbidity, previous lifestyle modification attempts, and referral to specialist weight management services (Tier 3)
A 2025 meta-analysis of 897 participants confirmed significant improvements in sleep onset latency and overall sleep quality
Discover the benefits of: Schedule your consultation and learn more about our cutting-edge wellness and anti-aging solutions
At Spa in the City, treatments are customized, monitored, and tailored to ensure safety and efficacy
Both peptides represent the next wave of treatments for people who have not found success with older options